Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | ACACA | Q13085 | 3/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599752 | 0.85 | SLC2A1 (0.56) | SLC2A1ALOX15MEN1KMT2ANPC1 | |
| SCHEMBL5667848 | 0.82 | SLC2A1 (0.54) | SLC2A1ALOX15MEN1KMT2ANPC1 | |
| SCHEMBL5670836 | 0.75 | SLC2A1 (0.50) | SLC2A1ALOX15MEN1KMT2ANPC1 | |
| SCHEMBL6606773 | 0.74 | SLC2A1 (0.71) | SLC2A1ALOX15MEN1KMT2AP2RY12 | |
| SCHEMBL6606672 | 0.73 | SLC2A1 (0.70) | SLC2A1ALOX15MEN1KMT2AGAA | |
| SCHEMBL16897058 | 0.73 | CTSK (0.49) | SYK | |
| SCHEMBL5742834 | 0.72 | CTSK (0.50) | MEN1KMT2AGAASYK | |
| SCHEMBL6607969 | 0.71 | SLC2A1 (0.57) | SLC2A1ALOX15MEN1KMT2A | |
| SCHEMBL20773522 | 0.71 | SYK (0.47) | GAASYK | |
| SCHEMBL4583612 | 0.71 | MAPT (0.54) | KMT2AGAASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040053963-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1351687-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1351687-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002047456-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063757-A1 | Urotensin-ll receptor antagonists | UTS2R, PLAUR, SCTR | SLC2A1 3284/4885ALOX15 2175/4885MEN1 3428/4885 |
| US-20040053963-A1 | Urotensin-II receptor antagonists | UTS2R, NTSR2, TMPRSS2 | SLC2A1 2614/4885ALOX15 3428/4885MEN1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.